Adverse Event Reporting through Mobile Health Tools
Mobile health (mHealth) technologies are revolutionizing adverse event (AE) reporting by enabling real-time, patient-driven data submission. Apps, SMS services, and wearable devices offer convenient, accessible platforms for capturing and transmitting AE information, particularly in remote or underserved regions. This digital shift enhances the timeliness, granularity, and volume of safety data collected across the product lifecycle. Patient-reported outcomes captured via mobile tools often provide richer context than traditional channels, including symptom severity, treatment adherence, and quality of life. Integration with electronic health records and centralized safety databases enables seamless data flow and analysis. Mobile interfaces also allow healthcare professionals to report AEs efficiently at the point of care. Ensuring data accuracy, privacy, and regulatory compliance remains crucial. Systems must align with global standards such as GVP, HIPAA, and GDPR. Additionally, user-friendly design and patient education are key to encouraging adoption. As digital health becomes embedded in pharmacovigilance, mobile tools will play a central role in democratizing drug safety reporting and enhancing signal detection capabilities.
Related Conference of Adverse Event Reporting through Mobile Health Tools
30th International Conference on Neuropharmacology and Neurochemistry
5th International Forum on Pharmacovigilance and Regulatory Affairs
Adverse Event Reporting through Mobile Health Tools Conference Speakers
Recommended Sessions
- Adverse Event Reporting through Mobile Health Tools
- AI-Driven Signal Detection and Data Mining
- Automation in Case Processing and Reporting
- Blockchain Applications in Regulatory Data Integrity
- Digital Transformation in Drug Safety Operations
- Ethics and Legal Challenges in Drug Safety Surveillance
- Global Harmonization of Regulatory Frameworks
- Global Signal Management Systems and Standards
- Inspection Readiness and Audit Best Practices
- Integration of PV with Quality and Regulatory Affairs
- Managing Safety Data in Multi-Region Submissions
- Patient-Centric Pharmacovigilance Strategies
- Pharmacovigilance Compliance in Clinical Trials
- Pharmacovigilance in Accelerated Drug Approvals
- Pharmacovigilance in Gene and Cell Therapies
- Pharmacovigilance Outsourcing and Vendor Oversight
- Real-World Evidence in Post-Marketing Surveillance
- Risk Management Planning and Benefit-Risk Assessment
- Safety Labeling Changes and Regulatory Communication
- Safety Monitoring of Biologics and Biosimilars
Related Journals
Are you interested in
- Artificial Intelligence in Neuropharmacological Drug Discovery - Neuropharmaceutics 2027 (Netherlands)
- Blood-Brain Barrier Pharmacology and Drug Delivery - Neuropharmaceutics 2027 (Netherlands)
- Brain-Computer Interfaces and Neurochemical Modulation - Neuropharmaceutics 2027 (Netherlands)
- Computational and Systems Neuropharmacology - Neuropharmaceutics 2027 (Netherlands)
- Digital Biomarkers and Neurochemical Monitoring Technologies - Neuropharmaceutics 2027 (Netherlands)
- Integrating Neurochemistry with Computational Brain Modeling - Neuropharmaceutics 2027 (Netherlands)
- Machine Learning Models in Neurochemical Data Analysis - Neuropharmaceutics 2027 (Netherlands)
- Molecular Mechanisms in Neuropharmacology - Neuropharmaceutics 2027 (Netherlands)
- Neurochemical Basis of Epilepsy and Anticonvulsant Pharmacology - Neuropharmaceutics 2027 (Netherlands)
- Neurochemical Basis of Mood Disorders and Emotional Regulation - Neuropharmaceutics 2027 (Netherlands)
- Neurochemical Big Data and Cloud-Based Pharmacology Platforms - Neuropharmaceutics 2027 (Netherlands)
- Neurochemical Biosensors and Real-Time Brain Monitoring - Neuropharmaceutics 2027 (Netherlands)
- Neurochemical Mechanisms in Neurodegenerative Disorders - Neuropharmaceutics 2027 (Netherlands)
- Neurochemical Signaling and Synaptic Transmission - Neuropharmaceutics 2027 (Netherlands)
- Neurochemistry of Addiction and Reward Pathways - Neuropharmaceutics 2027 (Netherlands)
- Neurochemistry of Neuroendocrine Regulation - Neuropharmaceutics 2027 (Netherlands)
- Neurochemistry of Psychiatric and Mood Disorders - Neuropharmaceutics 2027 (Netherlands)
- Neuroimaging Analytics and Computational Mapping of Brain Chemistry - Neuropharmaceutics 2027 (Netherlands)
- Neuroinflammation and Pharmacological Modulation - Neuropharmaceutics 2027 (Netherlands)
- Neuroinformatics and Computational Neuropharmacology - Neuropharmaceutics 2027 (Netherlands)
- Neuropharmacological Approaches to Pain and Analgesia - Neuropharmaceutics 2027 (Netherlands)
- Neuropharmacological Approaches to Pain Modulation and Analgesia - Neuropharmaceutics 2027 (Netherlands)
- Neuropharmacology of Addiction and Substance Abuse - Neuropharmaceutics 2027 (Netherlands)
- Neuropharmacology of Cognitive Function and Memory - Neuropharmaceutics 2027 (Netherlands)
- Neuropharmacology of Neurodegenerative Disorders - Neuropharmaceutics 2027 (Netherlands)
- Neuropharmacology of Neurodevelopmental and Autism Spectrum Disorders - Neuropharmaceutics 2027 (Netherlands)
- Neuropharmacology of Neuroplasticity and Neural Regeneration - Neuropharmaceutics 2027 (Netherlands)
- Neurotransmitter Receptors and Signal Transduction - Neuropharmaceutics 2027 (Netherlands)
- Precision Neuropharmacology through Artificial Intelligence and Genomic Profiling - Neuropharmaceutics 2027 (Netherlands)
- Virtual Drug Screening and Molecular Docking in Neuropharmacology - Neuropharmaceutics 2027 (Netherlands)
